Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals to $399 from $384 and keeps an Overweight rating on the shares post the Q2 “beat and raise.” The analyst continues to see the cystic fibrosis franchise to support the “floor value” with multiple near-term regulatory and data updates from pipeline assets to provide additional upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals raises FY23 CF product revenue to $9.7B-$9.8B
- Vertex Pharmaceuticals reports Q2 EPS $3.52, consensus $3.88
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex Pharmaceuticals price target raised to $400 from $350 at BofA
- Vertex Pharmaceuticals granted approval for label extension of Orkambi